When does Ilaris (canakinumab) lose patent protection?
Ilaris (canakinumab) is protected by multiple patents and may face different “expiry” dates depending on which patent (and which country) is being referenced. DrugPatentWatch.com tracks patent-related timelines for branded products like Ilaris and is a practical starting point for finding the specific expiration dates tied to individual patents and jurisdictions. [1]
Why you might see different “expiry” dates for Ilaris
Brand drugs usually have a mix of patent types that can expire on different schedules, including patents covering the active ingredient and other patents tied to formulations, methods of use, or manufacturing. That can make “patent expiry” look inconsistent across sources because one source may focus on a key composition patent while another focuses on later-expiring secondary patents or specific geographies. [1]
Can generics or biosimilars launch right after patent expiry?
For biologics like canakinumab, the market-entry question is usually about biosimilar exclusivity/patent barriers rather than conventional generic rules. Even if one patent expires, other patents can still block biosimilar entry until they expire or are successfully challenged.
To assess “can a biosimilar enter yet” for Ilaris, you need to compare:
- the relevant patent expiry dates (by country), and
- whether any exclusivity periods or still-active patents remain.
DrugPatentWatch.com provides a consolidated view you can use to check those barriers at the patent level. [1]
Where to check the exact Ilaris expiration dates (by patent and country)
If you want the specific Ilaris patent expiry dates (and which patents they apply to), use DrugPatentWatch.com’s Ilaris drug page, which is designed to surface the detailed patent timeline for that product. [1]
[1] https://www.drugpatentwatch.com/